scPharmaceuticals is developing Furoscix, a proprietary, subcutaneously delivered furosemide solution, as an outpatient alternative for the treatment of worsening heart failure due to congestion.
The FDA indicated that this was a complete class 2 response and assigned a Prescription Drug User-Fee Act (PDUFA) target action date of December 30, 2020.
Furoscix is a proprietary furosemide solution formulated to a neutral pH to allow for subcutaneous infusion via a wearable, pre-programmed on-body drug delivery system, for outpatient self-administration.
Furoscix is being developed for treatment of congestion, or fluid overload, in patients with heart failure.
Furoscix has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes.
The company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions.
The company's lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease.
scPharmaceuticals is headquartered in Burlington, MA.
Mycovia Pharmaceuticals reports first participant enrolled in Phase 2 cryptococcal meningitis study
bioMérieux launches rapid PCR test for equine respiratory diseases
Ondine Biomedical joins CAN Health Network to advance Steriwave adoption in Canada
Seegene presrnts CURECA conceptual video at ESCMID Global 2025
GC Biopharma's BARYTHRAX receives Korean regulatory approval
Seegene Inc developing fully automated PCR solution
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Ondine Biomedical's Steriwave technology reduces surgical site infections by 71% in NHS deployment
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100